NEW YORK (TheStreet) -- Endocyte
(ECYT - Get Report) plummeted approximately 25% in after-hours trading on Tuesday after the biopharmaceutical company announced Merck
(MRK), through a subsidiary, would no longer pursue development of vintafolide, aka Vynfinit.
Endocyte said it has regained worldwide rights to the ovarian cancer drug and will evaluate Vynfinit "for future development opportunities."
Endocyte's stock plummeted on May 2 when the drug failed in a Phase III study. For more on that, read TheStreet's Adam Feuerstein's story here.
Must Read: Endocyte Falls on Ovarian Cancer Drug BlowupSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was down 23.7% to $5.89 at 4:34 p.m. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts